CA 27-29 in patients with breast cancer with pulmonary fibrosis

A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).

Cancers, Free Full-Text

Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors

Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors

CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases

Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: a retrospective case-control study

PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Dr. Maurice R. Grant, MD, Morgantown, WV, Pathologist

Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review - ScienceDirect

MedPix Case - Diagnosis: 64 y.o. female with recurrent breast cancer with metastasis to lymph nodes and lungs. Liver mass biopsy reveals adenocarcinoma, with histology consistent with breast tissue.

Construction and validation of an immunity-related prognostic signature for breast cancer

CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases

PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Tumor Markers: Definition and Examples